EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular risk factors for locoregional recurrence in resected non‐small cell lung cancer

Wei Guo iD, Tao Zhang, Runze Li, Xiaoxi Chen iD, Jiaohui Pang, Hua Bao, Xue Wu, Yang Shao, Bin Qiu, Shugeng Gao, Jie He

Cancer Medicine · 2023-07 · 12 (14) · 15026-15036

DOI: 10.1002/cam4.6165 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 29.05.2023. Verfasst von Wei Guo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Municipal Science and Technology Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Locoregional recurrence is of high risk and is associated with a poor prognosis in terms of OS for non‐small cell lung cancer (NSCLC). Local control is essential for radical cure of NSCLC. Previous studies have investigated the clinicopathological risk factors for locoregional recurrence, but the genomic biomarkers associated with locoregional recurrence have been inadequately studied.

Methods

A total of 118 patients who underwent tumor resection with mutation‐detected tumor specimens were included. Tumor samples at surgery and pretreatment/postoperative blood samples were collected for mutational profiling.

Results

Among 48 patients with disease recurrence, 46% developed locoregional recurrence (LR) and 75% developed distant metastasis (DM). The 3‐year actuarial risk of LR and DM was 25% and 43%, respectively. The first sites of failure were locoregional only (29%), locoregional and distant (10%), and distant only (61%). Patients with LR showed significantly higher ctDNA level than those with only DM at the time of initial recurrence. On multivariate analysis of baseline risk factors, the presence of allele frequency heterogeneity and baseline ctDNA shedding were found to be independently associated with a higher risk of LR. Patients with disruptive TP53 mutations had significantly lower LR‐free survival as compared to patients with wild‐type TP53 or nondisruptive mutations. EGFR mutations showed a favorable prognostic value for LR and is not induced by EGFR tyrosine kinase inhibitor therapy. Both disruptive TP53 mutation and EGFR mutation remained the significant prognostic factor after adjustment for histological type, pathologic nodal stage and adjuvant therapy.

Conclusions

Nearly half of disease recurrences after surgery for NSCC involved locoregional sites. We identified genomic biomarkers from baseline tumor and ctDNA samples which showed promising prognostic value for LR only. This can help identify patients who had a higher risk of locoregional recurrence regardless of the risk of distant metastasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansNeoplasm Recurrence, LocalPrognosisRisk FactorsBiomarkersErbB ReceptorsRetrospective Studies

Stichwörter der Autor:innen

NSCLCadjuvant therapybiomarkersdistant recurrencelocoregional recurrence

Substanzen

BiomarkersErbB Receptors

Autor:innen und Institutionen

  • Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
  • Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China.
  • School of Public Health, Nanjing Medical University, Nanjing, China.

ORCID-Profile: Wei Guo, Xiaoxi Chen

Förderung

  • Beijing Municipal Science and Technology Commission

Zitieren

APA

Guo, W., Zhang, T., Li, R., Chen, X., Pang, J., Bao, H., Wu, X., Shao, Y., Qiu, B., Gao, S., & He, J. (2023). Molecular risk factors for locoregional recurrence in resected non‐small cell lung cancer. Cancer Medicine, 12(14), 15026-15036. https://doi.org/10.1002/cam4.6165

Vancouver

Guo W, Zhang T, Li R, Chen X, Pang J, Bao H, et al. Molecular risk factors for locoregional recurrence in resected non‐small cell lung cancer. Cancer Medicine. 2023;12(14):15026-15036. doi:10.1002/cam4.6165

BibTeX
@article{Guo2023,
  author = {Guo, Wei and Zhang, Tao and Li, Runze and Chen, Xiaoxi and Pang, Jiaohui and Bao, Hua and Wu, Xue and Shao, Yang and Qiu, Bin and Gao, Shugeng and He, Jie},
  title = {Molecular risk factors for locoregional recurrence in resected non‐small cell lung cancer},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {14},
  pages = {15026--15036},
  doi = {10.1002/cam4.6165}
}
Kostenlos starten →